TY - JOUR
T1 - MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent:
T2 - initial results in patients
AU - Spuentrup, E
AU - Botnar, RM
AU - Wiethoff, AJ
AU - Ibrahim, T
AU - Kelle, S
AU - Katoh, M
AU - Ozgun, M
AU - Nagel, E
AU - Vymazal, J
AU - Graham, PB
AU - Gunther, RW
AU - Maintz, D
PY - 2008/9
Y1 - 2008/9
N2 - This study was an initial phase II trial in humans of molecular magnetic resonance (MR) imaging for improved visualization of thrombi in vessel territories potentially responsible for stroke using a new fibrin-specific contrast agent (EP-2104R). Eleven patients with thrombus in the left ventricle (n = 2), left or right atrium (n = 4), thoracic aorta (n = 4) or carotid artery (n = 1) as verified by an index examination (ultrasound, computed tomograpy, or conventional MR) were enrolled. All MR imaging was performed on 1.5 T whole-body MR-system using an inversion-recovery black-blood gradient-echo sequence. The same sequence was performed before and 2–6 h after low-dose intravenous administration of 4 μmol/kg EP-2104R. Two investigators assessed image quality and signal amplification. Furthermore, contrast-to-noise ratios (CNR) between the clot and the blood pool/surrounding soft tissue before and after administration of the contrast agent were compared using Student’s t-test. MR imaging and data analysis were successfully completed in 10 patients. No major adverse effects occurred. On enhanced images, thrombi demonstrated high signal amplification, typically at the clot surface, with a significantly increased contrast in comparison to the surrounding blood pool and soft tissue (CNR for clot vs. blood pool, unenhanced and enhanced: 6 ± 8 and 29 ± 14; CNR for clot vs. soft tissue, unenhanced and enhanced: 0 ± 4 and 21 ± 13; P < 0.01 for both comparisons). EP-2104R allows for molecular MR imaging of thrombi potentially responsible for stroke. High contrast between thrombus and surrounding blood and soft tissues can be achieved with enhanced imaging.
AB - This study was an initial phase II trial in humans of molecular magnetic resonance (MR) imaging for improved visualization of thrombi in vessel territories potentially responsible for stroke using a new fibrin-specific contrast agent (EP-2104R). Eleven patients with thrombus in the left ventricle (n = 2), left or right atrium (n = 4), thoracic aorta (n = 4) or carotid artery (n = 1) as verified by an index examination (ultrasound, computed tomograpy, or conventional MR) were enrolled. All MR imaging was performed on 1.5 T whole-body MR-system using an inversion-recovery black-blood gradient-echo sequence. The same sequence was performed before and 2–6 h after low-dose intravenous administration of 4 μmol/kg EP-2104R. Two investigators assessed image quality and signal amplification. Furthermore, contrast-to-noise ratios (CNR) between the clot and the blood pool/surrounding soft tissue before and after administration of the contrast agent were compared using Student’s t-test. MR imaging and data analysis were successfully completed in 10 patients. No major adverse effects occurred. On enhanced images, thrombi demonstrated high signal amplification, typically at the clot surface, with a significantly increased contrast in comparison to the surrounding blood pool and soft tissue (CNR for clot vs. blood pool, unenhanced and enhanced: 6 ± 8 and 29 ± 14; CNR for clot vs. soft tissue, unenhanced and enhanced: 0 ± 4 and 21 ± 13; P < 0.01 for both comparisons). EP-2104R allows for molecular MR imaging of thrombi potentially responsible for stroke. High contrast between thrombus and surrounding blood and soft tissues can be achieved with enhanced imaging.
U2 - 10.1007/s00330-008-0965-2
DO - 10.1007/s00330-008-0965-2
M3 - Article
VL - 18
SP - 1995
EP - 2005
JO - European Radiology
JF - European Radiology
IS - 9
M1 - N/A
ER -